AIDS patients frequently develop central nervous system (CNS) lymphomas, for which there is currently no effective treatment. These AIDS-related CNS lymphomas all carry the Epstein-Barr virus (EBV) genome and express the EBV protein, EBNA 1. The ubiquitous presence of EBV in the AIDS- related CNS lymphomas presents unique opportunities for targeting these malignant cells for destruction using gene therapy approaches. In addition, gene therapy strategies which distinguish between proliferating (tumor) versus nonproliferating (neuronal) cells, and which have already been shown to cure glioblastomas in animal models, may likewise be useful in the treatment of CNS lymphomas. In these studies, we propose to use a recently developed SCID mouse model of CNS lymphoma to develop a variety of gene therapy approaches for the potential treatment of CNS lymphomas in AIDS. In our first specific aim, we will exploit the presence of EBV in AIDS-related CNS lymphomas and insert the """"""""suicide"""""""" gene HSV-TK (herpes simplex virus thymidine kinase), which confers ganciclovir sensitivity to cells, into a retroviral vector under the control of the EBV element, oriP. OriP, which contains both an origin of replication and a transcriptional enhancer element, requires the EBV protein EBNA 1 for function. In our second specific aim, we will insert the HSV-TK gene (under the control of the EBNA 1 dependent oriP enhancer element) into a plasmid vector and use the molecular-conjugate method to deliver DNA. The molecular conjugates will include a peptide containing the CD21 ligand (expressed on B cells) to specifically deliver the HSV-TK DNA only to tumor cells. In our third specific aim, we will attempt to induce lytic destruction of the EBV-infected lymphoma cells by using gene therapy to over-express the EBV immediate-early protein, BZLF1. Over-expression of BZLF1 is known to induce lytic EBV infection and consequent lysis of the host cell. In the final specific aim, we will examine the ability of defective HSV mutants to lyse EBV-transformed B cells in vitro, and cure EBV-induced CNS lymphomas in vivo. The studies proposed will not only be important in the development of an animal model system for AIDS-related CNS lymphomas, but should provide critical information regarding which therapeutic approaches are most promising for eventual human trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA066519-07
Application #
6350173
Study Section
Special Emphasis Panel (ZRG5-AARR-1 (01))
Project Start
1995-02-13
Project End
2003-01-31
Budget Start
2001-02-23
Budget End
2002-01-31
Support Year
7
Fiscal Year
2001
Total Cost
$223,950
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hoebe, Eveline; Wille, Coral; Hagemeier, Stacy et al. (2018) Epstein-Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor ?Np63? in Undifferentiated Nasopharyngeal Carcinoma. Cancers (Basel) 10:
Kenney, Shannon C; Mertz, Janet E (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26:60-8
Wille, Coral K; Nawandar, Dhananjay M; Panfil, Amanda R et al. (2013) Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol 87:935-50
Raver, Ryan M; Panfil, Amanda R; Hagemeier, Stacy R et al. (2013) The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol 87:8053-63
Robinson, Amanda R; Kwek, Swee Sen; Kenney, Shannon C (2012) The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog 8:e1002516
Hagemeier, Stacy R; Barlow, Elizabeth A; Meng, Qiao et al. (2012) The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol 86:13360-70
Ma, Shi-Dong; Yu, Xianming; Mertz, Janet E et al. (2012) An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 86:7976-87
Shaffer, Donald R; Savoldo, Barbara; Yi, Zhongzhen et al. (2011) T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117:4304-14
Hagemeier, Stacy R; Barlow, Elizabeth A; Kleman, Ariel A et al. (2011) The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner. J Virol 85:4318-29
Ma, Shi-Dong; Hegde, Subramanya; Young, Ken H et al. (2011) A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85:165-77

Showing the most recent 10 out of 43 publications